06Jun 2021
What is next in second- and later-line treatment of metastatic renal cell carcinoma? review of the recent literature

What is next in second- and later-line treatment of metastatic renal cell carcinoma? review of the recent literature

The current treatment landscape of metastatic renal cell carcinoma has changed dramatically from the dominance of single-agent tyrosine kinase inhibitor (TKI) therapy to immune-checkpoint inhibitor (ICI)-based combinations in recent years. However, the optimal subsequent therapy remains ill-defined owing to the novelty of this approach...

  • #urology

Like

Save

Share